News
Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer ...
PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in intraday trading.
Hosted on MSN24d
Sanofi to Acquire Blueprint Medicines for $9.1 Billion - MSNSanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases. The purchase includes a 27% premium per share and could total nearly $9.5 ...
Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, the companies said today, in a deal designed to expand the buyer’s rare immunological disease portfolio ...
France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...
Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 ...
6d
Pharmaceutical Technology on MSNDoH – Abu Dhabi and Sanofi link for vaccine developmentThe Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine ...
Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...
PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
Sanofi SAN-0.71%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC-0.05%decrease; red down pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...
PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results